NCT06733740 Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma
| NCT ID | NCT06733740 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese PLA General Hospital |
| Condition | Papillary Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2024-12-10 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2024-12-10 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate long-term outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma
Eligibility Criteria
Inclusion Criteria: 1. patients age between 18 and 80 year old, both sex 2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration 3. the largest diameter ≤2.0 cm 4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT 5. follow-up period ≥12 months Exclusion Criteria: 1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy 2. history of neck radiation 3. coagulation disorder, serious heart, respiratory, liver, or renal failure 4. dysfunction of the vocal cord on the opposite side
Contact & Investigator
Yukun Luo
PRINCIPAL INVESTIGATOR
Chinese PLA General Hospital
Frequently Asked Questions
Who can join the NCT06733740 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Papillary Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06733740 currently recruiting?
Yes, NCT06733740 is actively recruiting participants. Contact the research team at gemma-y@163.com for enrollment information.
Where is the NCT06733740 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06733740 clinical trial?
NCT06733740 is sponsored by Chinese PLA General Hospital. The principal investigator is Yukun Luo at Chinese PLA General Hospital. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.